Skip to main content

Praxis Precision Medicines, Inc.

corporate_fare Company Profile

Praxis Precision Medicines, Inc.

PRAX·NASDAQ·Life Sciences·CIK 0001689548

We are a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company. We translate insights from genetic epilepsies to develop therapies for CNS disorders marked by an imbalance in neuronal excitation and inhibition. Normal brain function relies on a delicate balance of excitation and inhibition in neuronal circuits, and dysregulation can lead to abnormal function and neurological disorders. We apply genetic insights to discover and develop therapies for neurological disorders using two proprietary platforms, based on our understanding of shared biological targets and circuits in the brain. Each platform currently has multiple programs with potential for expansion. Our Cerebrum™ platform, for small molecules, uses a deep understanding of neuronal excitability and networks, applying computational and experimental tools to develop orally available precision therapies. Our Solidus™ platform, for antisense oligonucleotides (ASO), is an efficient, targeted precision medicine discovery and development engine built on a proprietary computational methodology. Both platforms use a patient-guided approach, leveraging translational tools like novel transgenic and predictive translational animal models and electrophysiology markers, to achieve proof-of-concept in patients efficiently. This approach has resulted in a diversified, multimodal CNS portfolio with four clinical-stage product candidates for movement disorders and epilepsy. Cerebrum™ uses computational and experimental tools to discover and develop CNS small molecule therapies. Our ion channel discovery science team and collaborators create and execute novel screening cascades for selected genetic targets. Our multiscale disease models link genetic causes to network function to identify disease drivers. We use translational biomarkers like quantitative electroencephalography (qEEG) to guide dose selection. Genomics and informatics guide the precision application of our candidates to identify, stratify, and activate patients for trial recruitment and execution.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for PRAX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Praxis Precision Medicines Secures $621.2M in Public Offering to Extend Cash Runway into 2028
  • Praxis Precision Medicines Announces $575M Common Stock Offering at Discounted Price
  • Praxis Precision Medicines Reports Strong $925M Cash Position

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$303.27M
Diluted EPS
-$13.48
Op. Cash Flow
-$249.07M
Free Cash Flow
-$249.12M
Operating Income
-$326.2M
Cash & Equivalents
$357.33M
Debt / Equity
0.00×
Shares Outstanding
25.2M sh
Source: 10-K · filed 2026-02-19 · accession 0001689548-26-000029
$275 -8.46% today
52-week range · as of 2026-11-12 $160.11 – $392.7
Market cap
$8.4B
Volume
806.2K (1.5× avg)
3-mo avg 541.2K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PRAX - Filings & News (Page 2)

PRAX
Jan 07, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $292.37
Real-time Price: $275.00 info
Change: -$17.37 (-6%) info
Market Cap: $8.397B info
PRAX
Jan 07, 2026, 5:19 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $292.37
Real-time Price: $275.00 info
Change: -$17.37 (-6%) info
Market Cap: $8.397B info
PRAX
Jan 06, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $283.15
Real-time Price: $275.00 info
Change: -$8.15 (-3%) info
Market Cap: $8.397B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets